Study S003269

A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess Pharmacokinetic and Pharmacodynamic Effects of CT-868 on the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM

ClinicalTrials.gov record

Registration

Registration: NCT04973111
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 32
Start: 2021-07-16
Primary completion: 2022-04-22
Lead sponsor: Carmot Therapeutics, Inc.
Conditions: Diabetes
Interventions: DRUG:CT-868 as SC Injection; DRUG:Placebo as SC Injection; DRUG:Active Comparator as SC Injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in insulin secretion rate and ambient glucose levels [Baseline up to 4 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.